Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals.

Oncology Briefings™: Application of Novel Therapies for the Treatment of Acute Myeloid Leukemia

Release Date: October 31, 2019
Expiration Date: October 31, 2020
Media: Internet - based

Activity Overview

The treatment landscape of acute myeloid leukemia (AML) has expanded with the many recent clinical developments, and many more therapies are undergoing clinical trial investigation. Treatment paradigms are changing to reflect new clinical data. To optimize outcomes for patients with AML, healthcare practitioners need to access and effectively apply these data. This program is designed to address important competence gaps among practitioners who treat patients with hematologic malignancies by discussing current methods for accurate diagnosis, risk stratification, and multidisciplinary treatment after initial diagnosis and for later lines of treatment.

This Oncology Briefings™ program will help clinicians acquire the knowledge to meet these challenges through a series of audio interviews with Gail J. Roboz, MD, an expert in AML, who will discuss diagnostic and treatment guidelines for AML; important considerations throughout treatment, such as the level of patient fitness and the definition of minimal residual disease (or measurable residual disease; and the application of novel strategies to manage toxicities and comorbidities that can be particularly challenging in patients with AML.

Benefits of Participating

  • Apply insight from a leading clinical investigator to clinical cases to optimally use targeted therapy for patients with AML
  • Listen to Gail J. Roboz, MD, discuss a recent clinical case that illustrates challenges discussed in this program
  • Implement strategies to manage AML with agents that are current and support best practice care
  • Learn about important caveats to planning treatment regimens for difficult cases, such as those of older adults with AML
  • Implement increased knowledge of treatment options for relapsed/refractory AML to daily clinical practice

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Agios Pharmaceuticals.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audios/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Audio” will be available for your reference.
  • To receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational activity is directed toward hematologist/oncologists, medical oncologists, pathologists, and fellows from academic and community centers interested in the treatment of patients with AML.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Define best practices for risk stratification in patients with AML, methods of applying test results to patient care, and treatment monitoring strategies
  • Contextualize the results of recent clinical trials with recently approved and emerging treatment options to inform the appropriate management of patients with AML
  • Integrate optimized treatment approaches for AML, including treatment strategies indicated for elderly patients with AML
  • Identify strategies for prompt identification and proactive management of treatment-related toxicities across the continuum of care in patients with AML

Faculty, Staff, and Planners’ Disclosures


Gail J. Roboz
Gail J. Roboz, MD
Director, Clinical and Translational Leukemia Program
Department of Hematology
Professor of Medicine
Weill Cornell Medical College, Cornell University
Attending Physician, NewYork-Presbyterian Hospital
New York, NY

Disclosures: Consultancy or Advisory Board or Data and Safety Monitoring Committee: AbbVie, Actinium, Agios, Amphivena, Argenx, Array BioPharma, Astex, Astellas, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jazz, MEI Pharma (independent data monitoring committee chair), Novartis, Orsenix, Otsuka, Pfizer, Roche/Genentech, Sandoz, Takeda (independent review committee chair), Trovagene; Research Support: Cellectis.

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, PER® makes it a policy to ensure fair balance, independence, objectivity, and scientific rigor in all its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician and a nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support for this program.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By